WallStreetZenWallStreetZen

NASDAQ: BCAB
Bioatla Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BCAB

Based on 1 analyst offering 12 month price targets for Bioatla Inc

Min Forecast
$1.00+194.99%
Avg Forecast
$1.00+194.99%
Max Forecast
$1.00+194.99%

Should I buy or sell BCAB stock?

Based on 1 analyst offering ratings for Bioatla Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BCAB stock forecasts and price targets.

BCAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31

1 of 1

Forecast return on equity

Is BCAB forecast to generate an efficient return?

Company
-347.99%
Industry
153.19%
Market
81.87%
BCAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BCAB forecast to generate an efficient return on assets?

Company
-94.69%
Industry
36.07%
BCAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCAB earnings per share forecast

What is BCAB's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.18
Avg 2 year Forecast
-$1.44
Avg 3 year Forecast
-$1.07

BCAB revenue growth forecast

How is BCAB forecast to perform vs Biotechnology companies and vs the US market?

Company
55.53%
Industry
65.48%
Market
10.37%
BCAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BCAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BCAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCAB$0.34$1.00+194.99%Buy
LSTA$2.28$15.00+557.89%Buy
CVM$0.26N/AN/A
OVID$0.29$3.50+1,128.07%Strong Buy
CDIO$0.37N/AN/A
View Top Biotech Stocks

Bioatla Stock Forecast FAQ

Is Bioatla Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BCAB) stock is to Buy BCAB stock.

Out of 1 analyst, 0 (0%) are recommending BCAB as a Strong Buy, 1 (100%) are recommending BCAB as a Buy, 0 (0%) are recommending BCAB as a Hold, 0 (0%) are recommending BCAB as a Sell, and 0 (0%) are recommending BCAB as a Strong Sell.

If you're new to stock investing, here's how to buy Bioatla stock.

What is BCAB's earnings growth forecast for 2025-2027?

(NASDAQ: BCAB) Bioatla's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Bioatla's earnings in 2025 is -$69,776,000.On average, 1 Wall Street analyst forecast BCAB's earnings for 2025 to be -$68,913,353, with the lowest BCAB earnings forecast at -$68,913,353, and the highest BCAB earnings forecast at -$68,913,353. On average, 1 Wall Street analyst forecast BCAB's earnings for 2026 to be -$84,097,652, with the lowest BCAB earnings forecast at -$84,097,652, and the highest BCAB earnings forecast at -$84,097,652.

In 2027, BCAB is forecast to generate -$62,489,227 in earnings, with the lowest earnings forecast at -$62,489,227 and the highest earnings forecast at -$62,489,227.

What is BCAB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BCAB) forecast ROE is -347.99%, which is considered weak.

What is BCAB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BCAB price target, the average BCAB price target is $1.00, with the highest BCAB stock price forecast at $1.00 and the lowest BCAB stock price forecast at $1.00.

The Wall Street analyst predicted that Bioatla's share price could reach $1.00 by Mar 31, 2026. The average Bioatla stock price prediction forecasts a potential upside of 194.99% from the current BCAB share price of $0.34.

What is BCAB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BCAB) Bioatla's current Earnings Per Share (EPS) is -$1.44. On average, analysts forecast that BCAB's EPS will be -$1.18 for 2025, with the lowest EPS forecast at -$1.18, and the highest EPS forecast at -$1.18. On average, analysts forecast that BCAB's EPS will be -$1.44 for 2026, with the lowest EPS forecast at -$1.44, and the highest EPS forecast at -$1.44. In 2027, BCAB's EPS is forecast to hit -$1.07 (min: -$1.07, max: -$1.07).

What is BCAB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BCAB) forecast ROA is -94.69%, which is lower than the forecast US Biotechnology industry average of 36.07%.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.